New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 29, 2014
08:15 EDTSIEGY, LIFE, BDX, ABT, RHHBY, ILMN, A, ENZ, LMNX, HOLX, AFFXEnzo Biochem announces August 18 as date of Markman hearing in lawsuit
Enzo Biochem (ENZ) announced today that U.S. District Judge Leonard P. Stark has established August 18th as the date for a patent claim construction hearing, also called a Markman hearing, involving Enzo Life Science’s U.S. Patents Nos. 6,992,180, 7,064,197, and 8,097,405. The hearing will be held in Delaware District Court. One or more of these patents is asserted against Abbott Labs (ABT), Affymetrix (AFFX), Agilent (A), Becton Dickinson (BDX), Gen-Probe, Hologic (HOLX), Illumina (ILMN), Life Technologies (LIFE), Luminex (LMNX), Roche (RHHBY), and Siemens (SIEGY), and their related entities. At such a hearing, the Judge will be asked to issue rulings regarding the language and interpretation of Enzo's patents at issue in the case. Markman hearings are considered a key event in a patent lawsuit. The upcoming Markman ruling will define the property rights for the technologies that Enzo has invented. Such rulings often drive and inform many aspects of the litigation.
News For ENZ;ABT;AFFX;A;BDX;HOLX;ILMN;LIFE;LMNX;RHHBY;SIEGY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
July 21, 2015
19:00 EDTILMNOn The Fly: After Hours Movers
Subscribe for More Information
16:24 EDTILMNIllumina drops sharply after results
Subscribe for More Information
16:16 EDTILMNIllumina reports Q2 cash flow from operations of $171M, free cash flow $130M
16:15 EDTILMNIllumina reports Q2 gross margin 69.8% vs. 67.1% a year ago
16:15 EDTILMNIllumina raises FY15 adjusted EPS view to $3.39-$3.45 from $3.36-$3.42
Subscribe for More Information
16:13 EDTILMNIllumina reports Q2 adjusted EPS 80c, consensus 77c
Subscribe for More Information
15:02 EDTABTNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's open, with earnings consensus, include Coca-Cola (KO), consensus 60c... Boeing (BA), consensus $1.42... Abbott Laboratories (ABT), consensus 50c... Thermo Fisher Scientific (TMO), consensus $1.78... EMC (EMC), consensus 41c... Illinois Tool Works (ITW), consensus $1.28... St. Jude Medical (STJ), consensus $1.00... Northern Trust (NTRS), consensus 96c... Check Point Software (CHKP), consensus 95c... Polaris Industries (PII), consensus $1.58... Interpublic Group (IPG), consensus 27c... New York Community Bancorp (NYCB), consensus 26c... B/E Aerospace (BEAV), consensus 76c... Owens Corning (OC), consensus 54c... Knight Transportation (KNX), consensus 37c.
15:02 EDTILMNNotable companies reporting after market close
Subscribe for More Information
07:05 EDTRHHBYOphthotech names Shima as Chief Scientific Officer, Bjarke as CCO
Subscribe for More Information
July 20, 2015
19:22 EDTSIEGYPemex paid $295M to settle Siemens dispute, Reuters says
Subscribe for More Information
09:02 EDTABTAbbott receives FDA approval and launches iDesign Advanced WaveScan system
Subscribe for More Information
08:38 EDTABTAnalyst predicts Zoetis merges with Bayer unit, not Valeant
Zoetis (ZTS) in recent months has been the subject of takeover speculation, possibly for Valeant (VRX), but a Jefferies analyst told investors today in a research note that he views a deal with a unit of healthcare giant Bayer (BAYRY) as "highly likely" for the animal medicine company. BACKGROUND: Bill Ackman of Pershing Square, who owns stakes in both Zoetis and Valeant, said in early May while speaking on CNBC that Zoetis is a "great” business on a standalone basis, but he also spoke of the company's strategic value. Ackman added, however, that he was "not sure" that Valeant was the best acquirer of Zoetis. Subsequently, in late June, The Wall Street Journal reported that Valeant made a preliminary approach regarding a potential deal to buy Zoetis. CNBC's David Faber said the next day, citing his own sources, that Valeant reached out to Zoetis as a courtesy to common shareholder Ackman and was unlikely to pursue an acquisition of the company, though he cautioned then Valeant could change its approach and pursue a deal. BAYER: Jefferies analyst Jeffrey Holford said in a note today that he views a tie-up between Zoetis and Bayer's Animal Health business in 2016 as "highly likely." He sees Mylan's (MYL) acquisition of Abbott's (ABT) non‑U.S. developed markets specialty and branded generics business as a potential proxy for how a transaction could be structured, adding that such a "spinversion" could achieve up to 36% long-term earnings accretion for Zoetis. Holford reiterated a Buy rating on Zoetis with a $60 price target, while downgrading Bayer to Hold, citing valuation following the recent outperformance of its shares. IDEXX: While being discussed as a target, some analysts have also opined on companies that Zoetis could pursue as a buyer. On June 29, Canaccord said that in investor meetings with IDEXX (IDXX) executives declined to comment on Zoetis' potential interest in scaling up its animal health diagnostics business. Canaccord added that it thought Zoetis could make a bid for IDEXX. The firm reiterated its Buy rating and $80 price target on IDEXX shares at that time. PRICE ACTION: Since June 25, the day the Journal first reported on Valeant's preliminary takeover approach to Zoetis, the animal health company's shares have dropped nearly 4%. Zoetis closed down 20c to $47.80 on Friday.
07:33 EDTHOLX, ABT, RHHBYInternational AIDS Society to hold a conference
Subscribe for More Information
07:32 EDTLIFEaTyr Pharma announces transitions in clinical developments
Subscribe for More Information
07:30 EDTABTZoetis 'highly likely' to merge with Bayer unit in 2016, says Jefferies
Subscribe for More Information
06:32 EDTAFFXAffymetrix and Cytox announce strategic partnership
Subscribe for More Information
06:17 EDTILMNMizuho sees Q2 earnings beats in Diagnostics space
Subscribe for More Information
05:13 EDTRHHBYRoche expands HIV Global Access Program
Roche announced an expansion to the HIV Global Access Program to include early infant HIV diagnostic testing for low and middle income countries. Roche, in partnership with the Joint United Nations Programme on HIV/AIDS, or UNAIDS, the Clinton Health Access Initiative, or CHAI, UNITAID, the U.S. President's Emergency Plan For AIDS Relief, or PEPFAR, and the Global Fund to fight AIDS, TB and Malaria, is committed to working with the Diagnostics Access Initiative by providing state-of-the-art solutions to achieve the 90-90-90 goal set forth by UNAIDS. Announced in 2014, the HIV Global Access Program is Roche's most recent addition to the AmpliCare Initiative, which launched in 2002 in South Africa.
July 17, 2015
10:05 EDTILMNOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:55 EDTILMNIllumina initiated with a Buy at Canaccord
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use